Send to

Choose Destination
Leuk Lymphoma. 2002 May;43(5):1121-7.

A dual function anti-leukemic agent with anti-thrombotic activity.

Author information

Parker Hughes Cancer Center, Parker Hughes Institute, St Paul, MN 55113, USA.


Here we report that treatment with the anti-leukemic compound, LFM-A13 resulted in SYK kinase activation and caused distinct shape changes in platelets. Also provided is electron microscopic evidence that similar shape changes are observed in platelets from XID mice. We propose that LFM-A13 induces a conformational change in the PH domain of BTK and causes BTK to associate with PIP2 which effects actin bundling and shape change.

[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center